Who Paid My Doc
Matthew Konerman
Advanced Heart Failure and Transplant Cardiology Ann Arbor, MI Medical Doctor
NPI 1659557247 CMS profile 1394000
1500 E Medical Center Dr, Ann Arbor, MI 48109
General payments
$135
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$266,411
Through program year 2020, Matthew Konerman of Ann Arbor, MI is reported in the CMS Open Payments database as having received $135 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $266,411 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 3rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $135 | 1 |
Beside peers
- Matthew Konerman
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Matthew Konerman were reported at $0. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Matthew Konerman | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $863 | $224–$4,562 | $163 |
| 2020 | $135 | $452 | $122–$3,992 | $114 |
| 2021 | $0 | $550 | $159–$3,571 | $132 |
| 2022 | $0 | $729 | $221–$4,357 | $149 |
| 2023 | $0 | $1,002 | $309–$5,827 | $160 |
| 2024 | $0 | $931 | $273–$5,204 | $164 |
| 2025 | $0 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
3,461
Drug cost
$2,318,969
Branded share of claims
21.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vyndamax Tafamidis | Brand | 47 | $1,019,662 | |
| Vyndaqel Tafamidis Meglumine | Brand | 20 | $467,447 | |
| Jardiance Empagliflozin | Brand | 175 | $236,112 | |
| Eliquis Apixaban | Brand | 196 | $220,046 | |
| Entresto Sacubitril/Valsartan | Brand | 123 | $193,142 | |
| Xarelto Rivaroxaban | Brand | 39 | $45,424 | |
| Farxiga Dapagliflozin Propanediol | Brand | 31 | $33,941 | |
| Repatha Sureclick Evolocumab | Brand | 32 | $30,677 | |
| Torsemide | Generic | 230 | $9,960 | |
| Potassium Chloride | Generic | 170 | $9,306 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$23,007
Medicare patients
242
Services billed
388
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 73% | |
| Ischemic heart disease | 55% | |
| Atrial fibrillation | 51% | |
| Arthritis | 50% | |
| Chronic kidney disease | 47% | |
| Diabetes | 41% | |
| COPD | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Advanced Heart Failure and Transplant Cardiology in Michigan
Jennifer Cowger
Advanced Heart Failure and Transplant Cardiology · Detroit, MI
David Fermin
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MI
Michael Dickinson
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MI
Thomas Cascino
Advanced Heart Failure and Transplant Cardiology · Ann Arbor, MI
Sangjin Lee
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MI
Matthew Gonzalez
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MI
Related records
Advanced Heart Failure and Transplant Cardiology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.